Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024693 · ClinicalTrials.gov registry record · Phase 2
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
A Phase 2 study of Fuchs Endothelial Corneal Dystrophy and Fuchs, sponsored by Design Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT07024693: Recruiting Phase 2 study of Fuchs Endothelial Corneal Dystrophy and Fuchs, sponsored by Design Therapeutics.
NCT07024693 is a Phase 2 study of Fuchs Endothelial Corneal Dystrophy and Fuchs that is actively recruiting participants, run by Design Therapeutics. The registered enrollment target is 28 participants, below the 58-participant average among 3 other Fuchs Endothelial Corneal Dystrophy trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07024693, a Phase 2 study of Fuchs Endothelial Corneal Dystrophy and Fuchs, is actively recruiting participants, sponsored by Design Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
Primary Outcome
Assessment of DT-168 on splicing patterns in genes that are known to be disrupted in FECD.
Conditions Studied
Interventions
- DRUG DT-168
Study Locations (2)
Indiana
- DTX-168-201 Study Site - Indianapolis
Michigan
- DTX-168-201 Study Site - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT07024693 shows while recruiting
NCT07024693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 58-participant average among 3 other Fuchs Endothelial Corneal Dystrophy trials with a reported enrollment target (52% lower).
The record links to 2 conditions, with Fuchs Endothelial Corneal Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which DT-168 is the first listed.
NCT07024693 reports a single indexed study location in Indiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT07024693 about?
NCT07024693 is a clinical study titled "DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy". The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
What is the current status of trial NCT07024693?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2025-07-30. Estimated completion is 2026-12.
What conditions does trial NCT07024693 study?
This clinical trial studies the following conditions: Fuchs Endothelial Corneal Dystrophy, Fuchs.
What interventions are being tested in trial NCT07024693?
The interventions under investigation include: DT-168 (DRUG).
Who is sponsoring clinical trial NCT07024693?
This trial is sponsored by Design Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024693 being conducted?
This trial has 2 study locations across Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fuchs Endothelial Corneal Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
RECRUITING · Phase 2
-
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI